Who is sponsoring NCT00212680?

NCT00212680 is sponsored by Ono Pharma USA Inc.

What drugs are being tested in NCT00212680?

Interventions in NCT00212680: ONO-1101.

What condition does NCT00212680 study?

NCT00212680 studies Postoperative Supraventricular Tachyarrythmia.

Is NCT00212680 still recruiting?

NCT00212680 is currently completed. Last updated 10 October 2012.

Last reviewed 2012-10-10 · How we verify

NCT00212680

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Controlled Study of ONO-1101 in Patients With Postoperative Tachyarrhythmias in Japan

Completed Phase 2 Last updated 10 October 2012

What this trial tests

Phase 2 trial testing ONO-1101 in Postoperative Supraventricular Tachyarrythmia in 100 participants. Completed.

Timeline

1 December 1996

Primary endpoint
1 April 2006

Quick facts

Lead sponsor	Ono Pharma USA Inc
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	100
Start date	1 December 1996
Primary completion	1 April 2006

Drugs / interventions tested

ONO-1101 — full drug profile →

Conditions studied

Postoperative Supraventricular Tachyarrythmia — all drugs for Postoperative Supraventricular Tachyarrythmia →

Sponsor

Ono Pharma USA Inc — full company profile →

Who can join

Adults 21 to 79, any sex, with Postoperative Supraventricular Tachyarrythmia. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Percentage of patients achieving 20% reduction in heart rate at each dose

Sponsor's own description

The purpose of this study was to evaluate the dose-dependent effects of ONO-1101 on efficacy and safety in patients with postoperative supraventricular tachyarrhythmias.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00212680 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ono Pharma USA Inc
Last refreshed: 10 October 2012

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00212680.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing